Syngene Worldwide Ltd. on Thursday mentioned it has signed a 10-year settlement with animal well being firm, Zoetis, to fabricate the drug substance for Librela which is used for treating osteoarthritis in canine.This settlement, initially centred on Librela, paves the best way for growth and manufacturing of different molecules within the coming years and is predicted to be price as much as USD 500 million to Syngene in over 10 years, topic to regu…